Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Fluzone Intradermal Quadrivalent
(Influenza Vaccine) for
Intradermal Injection
Fluzone Intradermal Quadrivalent (Influenza Vaccine) for intradermal injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The Fluzone Intradermal Quadrivalent process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration. Antigens from the four strains included in the vaccine are produced separately and then combined to make the quadrivalent formulation.
Fluzone Intradermal Quadrivalent suspension for injection is clear and slightly opalescent in color.
Neither antibiotics nor preservative are used in the manufacture of Fluzone Intradermal Quadrivalent.
The Fluzone Intradermal Quadrivalent microinjection system is not made with natural rubber latex.
Fluzone Intradermal Quadrivalent is standardized according to United States Public Health Service requirements and is formulated to contain the following four influenza strains recommended for the 2016-2017 influenza season: A/California/07/2009 X-179A (H1N1), A/ Hong Kong/4801/2014 X-263B(H3N2), B/Phuket/3073/2013 (B Yamagata lineage), and B/ Brisbane/60/2008 (B Victoria lineage). The amounts of HA and other ingredients per dose of vaccine are listed in Table 3.
Table 3: Fluzone Intradermal Quadrivalent Ingredients aper
United States Public Health Service (USPHS) requirement
| Ingredient | Quantity per 0.1 mL Dose |
| Active Substance: Split influenza virus, inactivated strainsa: | 36 mcq HA total |
| A (H1N1) | 9 mcq HA |
| A (H3N2) | 9 mcq HA |
| B/(Victoria lineaqe) | 9 mcq HA |
| B/(Yamaqata lineaqe) | 9 mcq HA |
| Other: | |
| Sodium phosphate-buffered isotonic sodium chloride solution | QSb to appropriate volume |
| Formaldehyde | ≤ 20 mcq |
| Octylphenol ethoxylate | ≤ 55 mcq |
| aper United States Public Health Service (USPHS) requirement bQuantity Sufficient |
|
Fluzone® Intradermal Quadrivalent is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Intradermal Quadrivalent is approved for use in persons 18 through 64 years of age.
For intradermal use only
Fluzone Intradermal Quadrivalent should be administered as a single 0.1 mL injection by the intradermal route in adults 18 through 64 years of age.
Inspect Fluzone Intradermal Quadrivalent visually for particulate matter and/or discoloration prior to administration. If either of these conditions exist, the vaccine should not be administered.
The preferred site of injection is the skin in the region of the deltoid. Note: A potential way to make vaccination more efficient is to have the patient place the hand of the arm being immunized on his/her hip, so the arm bends at the elbow. This can help create a more accessible angle to the skin in the deltoid region.
Fluzone Intradermal Quadrivalent should not be combined through reconstitution or mixed with any other vaccine.
 |
1. Gently shake the device and remove needle cap
To prepare for vaccination, gently shake the device and remove needle cap before administering the vaccine.
 |
2. Position the device in your hand between the thumb and middle finger, keeping the index finger free
Hold the device by placing the thumb and middle finger on the finger pads above device window. Keep the index finger free.
 |
3. Gently pierce the skin over the deltoid region
Using light pressure, gently pierce the skin perpendicular to the deltoid region.
 |
4. Press the plunger to inject the vaccine
Using index finger, gently press the plunger to inject the vaccine. Do not aspirate. When the plunger stops, vaccination is complete. Note: Excessive pressure on the plunger may prematurely activate the needle shield on the patient's arm. Because the vaccine is injected into the skin, a wheal (superficial bump) and/or redness may be visible at the injection site.
 |
5. Activate the needle shield and dispose
Remove the needle from the skin. Direct the needle away from you and others. Push very firmly with the thumb on the plunger to activate the needle shield. You will hear a click when the shield extends to cover the needle. Dispose the device in an appropriate container.
 |
Fluzone Intradermal Quadrivalent is a suspension for injection.
Fluzone Intradermal Quadrivalent is supplied in a single-dose prefilled microinjection system, 0.1 mL, for adults 18 through 64 years of age.
Single-dose prefilled microinjection system, 0.1 mL (NDC 49281-710-48) (not made with natural rubber latex). Supplied as package of 10 (NDC 49281-710-40).
Store Fluzone Intradermal Quadrivalent refrigerated at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Discard if vaccine has been frozen.
Do not use after the expiration date shown on the label.
Manufactured by:Â Sanofi Pasteur Inc., Swiftwater PA 18370 USA. Revised: Jun 2016
In adults 18 through 64 years of age, the most common ( ≥ 10%) injection-site reactions were pain (53.3%), pruritus (52.1%), erythema (36.7%), swelling (19.5%), and induration (17.0%); the most common solicited systemic adverse reactions were myalgia (34.1%), headache (33.1%), malaise (27.7%), and shivering (12.1%).
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trial(s) of a vaccine cannot be directly compared to rates in the clinical trial(s) of another vaccine, and may not reflect the rates observed in practice.
Study 1 (NCT01712984, see http://clinicaltrials.gov) was a randomized, double-blind, active-controlled, multi-center safety and immunogenicity study conducted in the US. In this study, adults 18 through 64 years of age received a single injection of either Fluzone Intradermal Quadrivalent or one of two formulations of a comparator trivalent influenza vaccine by the intradermal route (TIV-ID1 or TIV-ID2). Each of the trivalent formulations contained an influenza type B virus that corresponded to one of the two type B viruses in Fluzone Intradermal Quadrivalent (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). The safety analysis set, comprised of all participants who received a study vaccine, included 3355 recipients. Among participants in the three vaccine groups combined, 61.3% were female, 84.9% White, 11.9% Black, 1.1% Asian, and 2.1% were of other racial/ethnic groups. Table 1 summarizes solicited injection-site and systemic adverse reactions reported within 7 days post-vaccination via diary cards. Participants were monitored for unsolicited adverse events for 28 days after vaccination and serious adverse events (SAEs) for 6 months after vaccination.
Table 1: Study 1a: Percentage of Solicited
Injection-site and Systemic Adverse Reactions Within 7 Days After Vaccination
in Adults 18 Through 64 Years of Age (Safety Analysis Set)b
| * | Fluzone Intradermal Quadrivalent (Ne=1649-1656) |
TIV-ID1 c (B Yamagata) (Ne=819-820) |
TIV-ID2d (B Victoria) (Ne=836-838) |
||||||
| Any (%) | Grade 2f (%) | Grade 3g (%) | Any (%) | Grade 2f (%) | Grade 3g (%) | Any (%) | Grade 2f (%) | Grade 3g (%) | |
| Injection-site adverse reactions | |||||||||
| Pain | 53.3 | 9.7 | 1.4 | 48.2 | 7.9 | 1.2 | 50.1 | 7.5 | 1.4 |
| Pruritis | 52.1 | 9.4 | 2.8 | 45.4 | 9.0 | 1.8 | 44.6 | 7.5 | 2.3 |
| Erythema | 36.7 | 10.9 | 0.4 | 34.0 | 9.8 | 0.1 | 32.1 | 6.3 | 0.4 |
| Swelling | 19.5 | 4.8 | 0.1 | 14.8 | 3.9 | 0.0 | 14.7 | 2.0 | 0.0 |
| Induration | 17.0 | 2.8 | < 0.1 | 13.5 | 1.8 | 0.0 | 11.2 | 2.2 | 0.0 |
| Ecchymosis | 2.6 | 0.4 | 0.0 | 1.8 | 0.4 | 0.0 | 1.8 | 0.1 | 0.0 |
| Systemic adverse reactions | |||||||||
| Myalgia | 34.1 | 8.1 | 2.6 | 29.0 | 8.2 | 1.5 | 31.1 | 7.4 | 2.5 |
| Headache | 33.1 | 9.1 | 3.2 | 31.3 | 9.6 | 2.4 | 33.2 | 8.9 | 1.8 |
| Malaise | 27.7 | 9.2 | 3.0 | 26.3 | 6.6 | 1.8 | 30.4 | 8.4 | 2.5 |
| Shivering | 12.1 | 2.0 | 1.4 | 10.4 | 2.2 | 0.6 | 11.2 | 3.3 | 1.6 |
| Fever ( ≥ 100.4°F)h | 0.8 | 0.2 | 0.2 | 0.7 | 0.2 | 0.1 | 0.5 | 0.0 | 0.0 |
| a NCT01712984 b The safety analysis set includes all persons who received study vaccine c TIV-ID1: 2012-2013 Fluzone Intradermal TIV containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Texas/6/2011 (Yamagata lineage), licensed d TIV-ID2: Investigational Intradermal TIV containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), non-licensed e N is the number of vaccinated participants with available data for the events listed f Grade 2 - Injection-site pain and injection-site pruritus: Some interference with activity; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis: ≥ 51 to ≤ 100 mm; Fever: ≥ 101.2°F to ≤ 102.0°F; Myalgia, Headache, Malaise, and Shivering: Some interference with activity g Grade 3 - Injection-site pain and injection-site pruritus: Significant - prevents daily activity; Injection-site erythema, Injection-site swelling, Injection-site induration, and Injection-site ecchymosis: > 100 mm; Fever: ≥ 102.1°F; Myalgia, Headache, Malaise, and Shivering: Significant - prevents daily activity h Fever measured by any route |
|||||||||
Unsolicited non-serious adverse events were reported in 382 (22.8%) recipients in the Fluzone Intradermal Quadrivalent group, 169 (20.2%) recipients in the TIV-ID1 group, and 212 (25.1%) recipients in the TIV-ID2 group. The most commonly reported unsolicited non-serious adverse events were cough, headache, and oropharyngeal pain. During the 28 days following vaccination, a total of 6 (0.4%) recipients in the Fluzone Intradermal Quadrivalent group, 2 (0.2%) recipients in the TIV-ID1 group, and 3 (0.4%) recipients in the TIV-ID2 group experienced at least one SAE; no deaths occurred. Throughout the study period (6 months post-vaccination), a total of 20 (1.2%) recipients in the Fluzone Intradermal Quadrivalent group, 14 (1.7%) recipients in the TIV-ID1 group, and 11 (1.3%) recipients in the TIV-ID2 group experienced at least one SAE. One death (177 days post-vaccination due to acute coronary myocardial infarction) occurred in the Fluzone Intradermal Quadrivalent group. This death was considered not related to the study vaccine by the Investigator.
The safety experience with Fluzone Intradermal (trivalent influenza vaccine) is relevant to Fluzone Intradermal Quadrivalent because both vaccines are manufactured using the same process and have overlapping compositions. In a study of adults 18 through 64 years of age (NCT00772109), safety was evaluated in 2855 Fluzone Intradermal recipients compared to 1421 Fluzone (trivalent influenza vaccine) recipients. Rates of solicited injection-site reactions and systemic adverse events in adults are shown in Table 2.
Table 2: Frequency of Solicited Injection-Site
Reactions and Systemic Adverse Events Within 7 Days After Vaccine Injection,
Adults 18 Through 64 Years of Age
| Fluzone Intradermal (Na=2798-2802) Percentage |
Fluzone (Na=1392-1394) Percentage |
|||||
| Any | Grade 2b | Grade 3c | Any | Grade 2b | Grade 3c | |
| Iniection-Site Erythema | 76.4 | 28.8 | 13.0 | 13.2 | 2.1 | 0.9 |
| Injection-Site Induration | 58.4 | 13.0 | 3.4 | 10.0 | 2.3 | 0.5 |
| Iniection-Site Swelling | 56.8 | 13.4 | 5.4 | 8.4 | 2.1 | 0.9 |
| Iniection-Site Pain | 51.0 | 4.4 | 0.6 | 53.7 | 5.8 | 0.8 |
| Iniection-Site Pruritus | 46.9 | 4.1 | 1.1 | 9.3 | 0.4 | 0.0 |
| Iniection-Site Ecchymosis | 9.3 | 1.4 | 0.4 | 6.2 | 1.1 | 0.4 |
| Headache | 31.2 | 6.4 | 1.5 | 30.3 | 6.5 | 1.6 |
| Myalgia | 26.5 | 4.6 | 1.5 | 30.8 | 5.5 | 1.4 |
| Malaise | 23.3 | 5.5 | 2.2 | 22.2 | 5.5 | 1.8 |
| Shivering | 7.3 | 1.5 | 0.7 | 6.2 | 1.1 | 0.6 |
| Feverd ( ≥ 99.5°F) | 3.9 | 0.6 | 0.1 | 2.6 | 0.4 | 0.2 |
| a N is the number of vaccinated subjects with
available data for the events listed b Grade 2 - Injection-site erythema, Injection-site induration, Injection-site swelling, and Injection-site ecchymosis: ≥ 2.5 cm to < 5 cm; Injection-site pain and Injection-site pruritus: sufficiently discomforting to interfere with normal behavior or activities; Fever: > 100.4°F to ≤ 102.2°F; Headache, Myalgia, Malaise, and Shivering: interferes with daily activities c Grade 3 - Injection-site erythema, Injection-site induration, Injection-site swelling, and Injection-site ecchymosis: ≥ 5 cm; Injection-site pain: incapacitating, unable to perform usual activities; Injection-site pruritus: incapacitating, unable to perform usual activities, may have/or required medical care or absenteeism; Fever: > 102.2°F; Headache, Myalgia, Malaise, and Shivering: prevents daily activities d Fever - The percentage of temperature measurements that were taken by oral or axillary routes, or not recorded were 99.9%, < 0.1%, and 0.1%, respectively, for Fluzone Intradermal; and 99.6%, 0.0%, and 0.4%, respectively, for Fluzone |
||||||
The following events have been spontaneously reported during the post-approval use of the trivalent formulation of Fluzone. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Adverse events were included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Fluzone.
No information provided.
Included as part of the PRECAUTIONS section.
If Guillain-Barr syndrome (GBS) has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Intradermal Quadrivalent should be based on careful consideration of the potential benefits and risks. The 1976 swine influenza vaccine was associated with an elevated risk of GBS. Evidence for a causal relation of GBS with other influenza vaccines is inconclusive; if an excess risk exists, it is probably slightly more than 1 additional case per 1 million persons vaccinated (See references 1 and 2).
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of Fluzone Intradermal Quadrivalent.
If Fluzone Intradermal Quadrivalent is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the expected immune response may not be obtained.
Vaccination with Fluzone Intradermal Quadrivalent may not protect all recipients.
See FDA-approved patient labeling (PATIENT INFORMATION). Inform the vaccine recipient or guardian:
Fluzone Quadrivalent has not been evaluated for carcinogenic or mutagenic potential. A reproductive study of female rabbits vaccinated with Fluzone Quadrivalent was performed and revealed no evidence of impaired female fertility [see Pregnancy].
Pregnancy Category B: The developmental and reproductive toxicity study performed with the trivalent formulation of Fluzone Intradermal is relevant to Fluzone Intradermal Quadrivalent because both vaccines share the same manufacturing process and route of administration. The study, in which the trivalent formulation of Fluzone Intradermal (27 mcg) was administered to female rabbits at a dose approximately 20 times the human dose (on a mg/kg basis), revealed no evidence of impaired female fertility or harm to the fetus. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Fluzone Intradermal Quadrivalent should be used during pregnancy only if clearly needed.
Sanofi Pasteur Inc. is maintaining a prospective pregnancy exposure registry to collect data on pregnancy outcomes and newborn health status following vaccination with Fluzone Intradermal Quadrivalent during pregnancy. Healthcare providers are encouraged to enroll women who receive Fluzone Intradermal Quadrivalent during pregnancy in Sanofi Pasteur Inc.'s vaccination pregnancy registry by calling 1-800-822-2463.
It is not known whether Fluzone Intradermal Quadrivalent is excreted in human milk. Because many drugs are excreted in human milk, the decision to give Fluzone Intradermal Quadrivalent to a nursing woman should be based on careful consideration of the potential benefits and risks.
Safety and effectiveness of Fluzone Intradermal Quadrivalent in persons < 18 years of age have not been established. In a clinical trial, 97 infants and toddlers 6 months through 35 months of age and 160 children 3 years through 8 years of age were enrolled to receive two injections of the trivalent formulation of Fluzone Intradermal. Infants and children in a control group received two injections of Fluzone. Fluzone Intradermal was associated with increased local reactogenicity relative to Fluzone. The size of the study was not adequate to reliably evaluate serious adverse events or the immune response elicited by Fluzone Intradermal relative to Fluzone.
Safety and effectiveness of Fluzone Intradermal Quadrivalent in persons 65 years of age and older have not been established.
REFERENCES
1 Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barr syndrome and the 1992- 1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
2 Baxter, R, et al. Lack of Association of Guillain-Barr Syndrome with Vaccinations. Clin Infect Dis 2013;57(2):197-204.
No information provided.
Do not administer Fluzone Intradermal Quadrivalent to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see DESCRIPTION], including egg protein, or to a previous dose of any influenza vaccine.
Influenza illness and its complications follow infection with influenza viruses. Global surveillance of influenza identifies yearly antigenic variants. Since 1977, antigenic variants of influenza A (H1N1 and H3N2) viruses and influenza B viruses have been in global circulation. Since 2001, two distinct lineages of influenza B (Victoria and Yamagata lineages) have cocirculated worldwide. Protection from influenza virus infection has not been correlated with a specific level of hemagglutination inhibition (HAI) antibody titer post-vaccination. However, in some human studies, antibody titers ≥ 1:40 have been associated with protection from influenza illness in up to 50% of subjects (See references 3 and 4).
Antibodies against one influenza virus type or subtype confer limited or no protection against another. Furthermore, antibodies to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. Frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual change of one or more new strains in each year's influenza vaccine. Therefore, influenza vaccines are standardized to contain the hemagglutinins of influenza virus strains, representing the influenza viruses likely to be circulating in the US during the influenza season.
Annual vaccination with the current vaccine is recommended because immunity during the year after vaccination declines, and because circulating strains of influenza virus change from year to year.
In Study 1 (NCT01712984), study participants were randomized to receive one dose of Fluzone Intradermal Quadrivalent, TIV-ID1, or TIV-ID2. Of the 2249 participants randomized to provide blood samples for immunogenicity analyses, 2113 adults 18 through 64 years of age were included in the per-protocol analysis set. The distribution of demographics was similar to that of the safety analysis set [see Clinical Trials Experience].
HAI antibody geometric mean titers (GMTs) and seroconversion rates 28 days following vaccination with Fluzone Intradermal Quadrivalent were non-inferior to those following each TIV-ID for all four strains, based on pre-specified criteria (see Table 4 and Table 5).
Table 4: Study 1a: Non-inferiority of
Fluzone Intradermal Quadrivalent Relative to TIV-ID for Each Strain by HAI
Antibody GMTs at 28 Days Post-Vaccination, Adults 18 Through 64 Years of Age
(Per-protocol Analysis Set)b
| Antigen Strain | Fluzone Intradermal Quadrivalent | Pooled TIV-IDc | GMT Ratio (95% CI)d | ||||
| Me | GMT | Me | GMT | ||||
| A (H1N1) | 1041 | 589 | 1072 | 680 | 0.87 (0.78; 0.97) |
||
| A (H3N2) | 1041 | 368 | 1071 | 430 | 0.86 (0.77; 0.96) |
||
| Fluzone Intradermal Quadrivalent | TIV-ID1f(B Yamagata) | TIV-ID2g(B Victoria) | GMT Ratio (95% CI)d | ||||
| Me | GMT | Me | GMT | Me | GMT | ||
| B/Texas/6/2011 (B Yamagata) | 1041 | 105 | 539 | 93.5 | 533 | O (5 | 1.13 (1.02; 1.25) |
| B/Brisbane/60/2008 (B Victoria) | 1041 | 136 | 538 | (66.7)i | 533 | 130 | 1.05 (0.94; 1.16) |
| aNCT01712984 b Per-protocol analysis set included all persons who underwent serologic testing and had no study protocol deviations cPooled TIV-ID group includes participants vaccinated with either TIV-ID1 or TIV-ID2 d Non-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the ratio of GMTs (Fluzone Intradermal Quadrivalent divided by pooled TIV-ID for the A strains, or the TIV-ID containing the corresponding B strain) was > 2/3 e M is the number of participants in the per-protocol analysis set with available data for the considered endpoint f TIV-ID1: 2012-2013 Fluzone Intradermal TIV containing A/California/7/2009 (H1N1), A/ Victoria/361/2011 (H3N2), and B/Texas/6/2011 (Yamagata lineage), licensed g TIV-ID2: Investigational Intradermal TIV containing A/California/7/2009 (H1N1), A/ Victoria/361/2011 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), non-licensed hTIV-ID2 did not contain B/Texas/6/2011 iTIV-ID1 did not contain B/Brisbane/60/2008 |
|||||||
Table 5: Study 1a: Non-inferiority of
Fluzone Intradermal Quadrivalent Relative to TIV-ID for Each Strain by
Seroconversion Rates at 28 Days Post-Vaccination, Adults 18 Through 64 Years of
Age (Per-protocol Analysis Set)b
| Antigen Strain | Fluzone Intradermal Quadrivalent | Pooled TIV-IDc | Difference of Seroconversion Rates (95% CI)f | ||||
| Md | Sero- conversione (%) | Md | Sero-conversione (%) | ||||
| A (H1N1) | 1041 | 57.6 | 1072 | 60.4 | -2.72 (-6.90; 1.47) | ||
| A (H3N2) | 1040 | 58.5 | 1071 | 59.8 | -1.30 (-5.48; 2.89) | ||
| Fluzone Intradermal Quadrivalent | TIV-ID1g (B Yamagata) | TIV-ID2h (B Victoria) | Difference of Seroconversion Rates (95% CI)f | ||||
| Md | Sero- conversione(%) | Md | Sero- conversione (%) | Md | Sero- conversione (%) | ||
| B/Texas/6/2011 (B Yamagata) | 1041 | 55.7 | 539 | 46.9 | 533 | (24.6)i | 8.78 (3.58; 13.9) |
| B/Brisbane/60/2008 (B Victoria) | 1041 | 50.4 | 538 | (22.1)j | 533 | 44.1 | 6.34 (1.13; 11.5) |
| aNCT01712984 b Per-protocol analysis set included all persons who underwent serologic testing and had no study protocol deviations cPooled TIV group includes participants vaccinated with either TIV-ID1 or TIV-ID2 d M is the number of participants in the per-protocol analysis set with available data for the considered endpoint e Seroconversion: Paired samples with pre-vaccination HAI titer < 1:10 and post-vaccination titer ≥ 1:40 or a minimum 4-fold increase for participants with pre-vaccination titer ≥ 1:10 f Non-inferiority was demonstrated if the lower limit of the 2-sided 95% CI of the difference in seroconversion rates (Fluzone Intradermal Quadrivalent minus pooled TIV-ID for the A strains, or the TIV-ID containing the corresponding B strain) was > -10% g TIV-ID1: 2012-2013 Fluzone Intradermal TIV containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Texas/6/2011 (Yamagata lineage), licensed h TIV-ID2: Investigational Intradermal TIV containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), and B/Brisbane/60/2008 (Victoria lineage), non-licensed iTIV-ID2 did not contain B/Texas/6/2011 jTIV-ID1 did not contain B/Brisbane/60/2008 |
|||||||
REFERENCES
3 Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-138.
4 Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutinationinhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg Camb 1972;70:767-777.
No information provided. Please refer to the WARNINGS AND PRECAUTIONS sections.
